Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)

BACKGROUND: Lenvatinib inhibits tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor alpha, RET proto-oncogene and KIT proto-oncogene, receptor tyrosine kinase. We assessed the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Satoru, Okita, Natsuko, Kuchiba, Aya, Ogawa, Gakuto, Kawasaki, Mamiko, Nakamura, Kenichi, Shoji, Hirokazu, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Boku, Narikazu, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440718/
https://www.ncbi.nlm.nih.gov/pubmed/32817132
http://dx.doi.org/10.1136/esmoopen-2020-000776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440718/
https://www.ncbi.nlm.nih.gov/pubmed/32817132
http://dx.doi.org/10.1136/esmoopen-2020-000776

Ejemplares similares